Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients.

ABSTRACT:

Background

Multiple myeloma (MM) is a complex heterogeneous disease. Various risk stratification models have been recommended including cytogenetic and FISH analysis to identify high-risk patients who may benefit from novel treatments, but such facilities are not widely available. The International Scoring System (ISS) using beta-2-microglobulin and albumin remains a widely used prognostic scoring system in many clinical practices; however it is not useful in predicting response to treatment in MM. The aim of this study is to identify clinically useful biomarkers to predict response to treatment containing bortezomib.

Methods

17 MM patient serum samples (9 responders/8 non-responders) were used for the discovery phase (label-free mass spectrometry) and an additional 20 MM pa

SUBMITTER: Ting KR 

PROVIDER: S-EPMC5502697 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature